Search research articles
Contact Us
Filters
Showing results (71-80 of 110) with videos related to
Page
of 11
Sort By:
British Journal of Haematology
|
August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial
Mary Gleeson, Eliza A Hawkes, David Cunningham, et al.
British Journal of Haematology
|
May 1, 2018
Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes
Susan K Parsons, Michael J Kelly, Joshua T Cohen, et al.
The Lancet. Oncology
|
May 14, 2021
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2018
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
Wolfgang Hiddemann, Anna Maria Barbui, Miguel A Canales, et al.
The Lancet. Oncology
|
October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Blood
|
June 9, 2022
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
Paola Ghione, M Lia Palomba, Anik R Patel, et al.
Haematologica
|
June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study
Andrew M Evens, Joseph M Connors, Anas Younes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2016
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
Gustaaf W van Imhoff, Andrew McMillan, Matthew J Matasar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma
Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
British Journal of Haematology
|
January 15, 2011
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
Peter Hillmen, Dena R Cohen, Kim Cocks, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 110) with videos related to
Sort By:
Page
of 11
British Journal of Haematology
|
August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial
Mary Gleeson, Eliza A Hawkes, David Cunningham, et al.
British Journal of Haematology
|
May 1, 2018
Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes
Susan K Parsons, Michael J Kelly, Joshua T Cohen, et al.
The Lancet. Oncology
|
May 14, 2021
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2018
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
Wolfgang Hiddemann, Anna Maria Barbui, Miguel A Canales, et al.
The Lancet. Oncology
|
October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
Blood
|
June 9, 2022
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
Paola Ghione, M Lia Palomba, Anik R Patel, et al.
Haematologica
|
June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study
Andrew M Evens, Joseph M Connors, Anas Younes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2016
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
Gustaaf W van Imhoff, Andrew McMillan, Matthew J Matasar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma
Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
British Journal of Haematology
|
January 15, 2011
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
Peter Hillmen, Dena R Cohen, Kim Cocks, et al.
Page
of 11